University of Pennsylvania School of Medicine | Sep 24, 2020
Researchers from Penn, in collaboration with the Ragon Institute, develop a new dual CAR T cell immunotherapy that combats HIV infection in humanized mice
The largest report of commercial CAR T therapy for lymphoma demonstrates its effectiveness even in patients that would not have been eligible for clinical trials
A new study addresses a central conundrum of CAR-T therapies: their tendency to provoke potentially deadly runaway immune responses against healthy tissues in patients
University of Chicago Medical Center | Dec 03, 2018
Forty percent of patients with diffuse large B-cell lymphoma had a complete response, most of which were durable
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.